Fanttest Biotech's 6-in-1 Respiratory Test Listed on Australia's ARTG (531589)
On 22 September 2026, Hangzhou Fanttest Biotech Co., Ltd. ("Fanttest") announced that its 6-in-1 respiratory antigen test has been entered in the Australian Register of Therapeutic Goods (ARTG 531589). The device is supplied in Australia by BIO TOP Pty Ltd.
The Fanttest 6-in-1 combo test is a rapid antigen test that qualitatively detects six respiratory pathogens from a single nasal swab: SARS-CoV-2 (COVID-19), human metapneumovirus (hMPV), respiratory syncytial virus (RSV), adenovirus (ADV), influenza A and influenza B. It uses a cassette format in which six test lines are arranged across three result windows, providing a clear and easy-to-read panel that distinguishes all six pathogens in one test and identifies multiple-positive results when two or more test lines appear simultaneously.
Respiratory viruses such as SARS-CoV-2, influenza A and B, RSV, hMPV and ADV are common causes of respiratory illness, with symptoms ranging from mild upper respiratory tract infection to more severe disease. Diagnostic approaches for respiratory infections include laboratory-based molecular methods such as RT-PCR, which require specialised equipment and trained personnel, and rapid antigen tests, which can be performed at the point of care and provide results within minutes.
The kit is available in pack sizes of 1, 2, 5, 7 and 10 tests per kit (REF IRV-565-A010 to IRV-565-A100) and should be stored at 2–30℃. The result should be read at 15 minutes and must not be interpreted after 20 minutes. It is suitable for self-testing by individuals aged 15 and above, with adult supervision required for younger users.
ARTG 531589 is a listing number stated for reference only and does not constitute an endorsement of performance. Please read all information in the instructions for use before performing the test. A negative result does not exclude infection;a positive result requires confirmation by a healthcare professional.
Post time: 11-20-2026

